Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Cybrexa 2 Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners, providing a broader base of interaction with the patent office than a single-examiner portfolio. The busiest examiner identified is MIKNIS, ZACHARY J, who is responsible for 1 busiest examiner pending action.
The prosecution activity is further divided between 2 distinct art units. This suggests that the company's Biotechnology & Pharmaceuticals applications cover different technical sub-specialties. With 2 pending office actions and 2 distinct examiners, the workload is spread across multiple individuals. For a patent practitioner, this distribution means that the company must manage separate prosecution tracks simultaneously. MIKNIS, ZACHARY J handles 1 busiest examiner pending action, while the remaining workload is managed by a different distinct examiner in a separate art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIKNIS, ZACHARY J | 1 | 68.5% | +32.4% |
| MEAH, MOHAMMAD Y | 1 | 70.7% | +42.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18288650 | DOSING REGIMENS OF PEPTIDE CONJUGATES OF TOPOISOMERASE I INHIBITORS | MIKNIS, ZACHARY J | — |
| 18271121 | PROCESS FOR PREPARING A CONJUGATE LINKING MOIETY | MEAH, MOHAMMAD Y | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18288650 | DOSING REGIMENS OF PEPTIDE CONJUGATES OF TOPOISOMERASE I INHIBITORS | MIKNIS, ZACHARY J | 1658 | §102§103DP | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18271121 | PROCESS FOR PREPARING A CONJUGATE LINKING MOIETY | MEAH, MOHAMMAD Y | 1652 | §112 | Non-Final OA | — | Pending | Jul 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCybrexa 2 Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Zachary J Miknis has the most, with 1 of Cybrexa 2 Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
